News for 'Good Manufacturing Practice'

'We Aren't Security Conscious As A Nation'

'We Aren't Security Conscious As A Nation'

Rediff.com6 Nov 2025

'Government officials use Gmail and ordinary phones without basic security consciousness.' 'Interoperability, especially in joint exercises with countries like the US, worries me.' 'It often means we open our systems to them, but they don't reciprocate.' 'They could have kill switches in their systems and might even be able to affect ours.'

Amazon, Flipkart deploy war rooms for Rs 1.2 trillion festival battle

Amazon, Flipkart deploy war rooms for Rs 1.2 trillion festival battle

Rediff.com23 Sep 2025

At the stroke of midnight, live dashboards lit up simultaneously across Amazon India's World Trade Centre headquarters and Flipkart's Outer Ring Road office in Bengaluru. In sprawling "war rooms" at both the companies, executives monitored real-time data streams tracking payment speeds, inventory levels, and delivery logistics as millions of shoppers flooded online platforms.

BYD's Latest EV Makes a Splash in Mumbai

BYD's Latest EV Makes a Splash in Mumbai

Rediff.com25 Jun 2025

The BYD Sealion 7 offers instant, exhilarating power, effortlessly pinning you to your seat with a 0-100 km/h sprint in just 4.5 seconds -- a performance proudly showcased on its rear badging.

Breaking up bad assets: Can IBBI's part-resolution rewire insolvency rules?

Breaking up bad assets: Can IBBI's part-resolution rewire insolvency rules?

Rediff.com7 Jul 2025

The recent notification by the Insolvency and Bankruptcy Board of India (IBBI) allowing part-resolution of stressed assets of companies under the insolvency process has sent many resolution professionals (RPs) and committees of creditors (CoCs) back to the drawing board to reassess their strategies for resolving corporate insolvencies.

USFDA raises concerns about Ranbaxy's Toansa plant

USFDA raises concerns about Ranbaxy's Toansa plant

Rediff.com13 Jan 2014

All of Ranbaxy's India-based factories are currently banned by the FDA from exporting medicines to the United States, the company's largest market, after the regulator's inspection found violation of its so-called good manufacturing practices.

AyushMin gets rap for underuse of funds despite rising allocation

AyushMin gets rap for underuse of funds despite rising allocation

Rediff.com27 Feb 2024

Given the gap between budgetary allocation and use, a parliamentary standing committee has asked the Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy (Ayush) to take steps to prevent underutilisation of funds under the National Ayush Mission (NAM) scheme. According to the data, the ministry was allocated Rs 1,200 crore for the mission in the Budgetary Estimate (BE) for FY24. The Revised Estimate (RE) for the year fell to Rs 815 crore, of which Rs 589 crore, or 74 per cent, has been spent till January.

USFDA issues import alert on Ranbaxy's Mohali plant

USFDA issues import alert on Ranbaxy's Mohali plant

Rediff.com16 Sep 2013

While the US health regulator did not specify details for issuing the alert, it said 'detention without physical examination may be appropriate when an FDA inspection has revealed that a firm is not operating in conformity with current good manufacturing practices'.

USFDA pulls up Sun Pharma for lapses in Halol plant

USFDA pulls up Sun Pharma for lapses in Halol plant

Rediff.com14 Jan 2023

The US health regulator has pulled up drug major Sun Pharma for manufacturing lapses, including failure to follow appropriate written procedures designed to prevent microbiological contamination of drug products, at its Gujarat-based plant. In a warning letter, the US Food and Drug Administration (USFDA) pointed out various lapses at the Halol plant which produces finished pharmaceutical products. "This warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals... Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated," the USFDA stated.

US drug regulator warns RPG Life Sciences

US drug regulator warns RPG Life Sciences

Rediff.com19 Jun 2013

The US Food and Drug Administration (USFDA) has issued a warning letter to RPG Life Sciences for violation of current good manufacturing practice (CGMP) norms at its two plants at Ankleshwar and Mumbai.

EV Sales Surge on Back of Government Push; Hybrids Lag

EV Sales Surge on Back of Government Push; Hybrids Lag

Rediff.com8 Jul 2025

Despite the benefits of hybrid technology, a lack of government backing and few launches have kept the segment from gaining ground.

After US, Germany bans export of Ranbaxy's Dewas plant drugs

After US, Germany bans export of Ranbaxy's Dewas plant drugs

Rediff.com3 Dec 2014

The company did not comply to the 'good manufacturing practice' norms.

Wockhardt gets import alert from US FDA

Wockhardt gets import alert from US FDA

Rediff.com6 Aug 2016

Ankleshwar plant is the third such facility to face action

Ranbaxy 'systematically violated' norms: Whistleblower

Ranbaxy 'systematically violated' norms: Whistleblower

Rediff.com14 May 2013

The generic drugs at issue were manufactured at Ranbaxy's facilities in Paonta Sahib and Dewas in India and included acne drug Sotret, epilepsy and nerve pain drug gabapentin and antibiotic ciprofloxacin.

P&G's New Boss Is Big Into Bollywood Movies

P&G's New Boss Is Big Into Bollywood Movies

Rediff.com30 Jul 2025

Shailesh Jejurikar has 'always made an effort to stay close to his roots.'

India imposes its own 'uniquely burdensome' rules: US

India imposes its own 'uniquely burdensome' rules: US

Rediff.com3 Apr 2025

On India, the chart showed that the country charged 52 per cent tariffs on the US "including currency manipulation and trade barriers," and America will now charge India "discounted reciprocal tariffs" of 26 per cent.

The Alaska Fiasco: Lessons For India

The Alaska Fiasco: Lessons For India

Rediff.com16 Aug 2025

The point to note for India is that we must not panic. The United States may be our largest export destination, but high tariffs will not exactly mean gloom and doom. Sure, we can throw some morsels as we continue negotiating, but we must be firm that some red lines cannot be crossed, no matter what, asserts Shreekant Sambrani.

WHO suspends Covaxin supply to UN agencies

WHO suspends Covaxin supply to UN agencies

Rediff.com3 Apr 2022

A statement issued by the WHO on Saturday said the suspension is in response to the outcomes of its post EUL (emergency use authorisation) inspection held between March 14-22, 2022 and the need to conduct process and facility upgrade to address recently identified GMP (good manufacturing practice) deficiencies.

Sun Pharma's US subsidiary to cut jobs

Sun Pharma's US subsidiary to cut jobs

Rediff.com30 Jul 2009

Earlier last month US FDA officials had seized drug products manufactured by Caraco Pharmaceutical at its Michigan facilities in Detroit, Farmington Hills, and Wixom, alleging violation in good manufacturing practice.

FDA warns Ranbaxy's American subsidiary

FDA warns Ranbaxy's American subsidiary

Rediff.com24 Dec 2009

The letter mentions certain cGMP violation based on site inspections conducted between July and August 2009.

'India Can Convert Tariffs Into Win-Win Situation'

'India Can Convert Tariffs Into Win-Win Situation'

Rediff.com11 Aug 2025

'It's important for India to think about areas where it wants the US to move.' 'We can be far more innovative in what we ask the US.' 'Given that there's a package deal, why not do it?'

US regulator not happy with Sun Pharma's reply on import alert

US regulator not happy with Sun Pharma's reply on import alert

Rediff.com21 May 2014

In March, the FDA had issued an import alert, banning formulations and active pharmaceutical ingredients from the factory.

'I Don't Want To Compromise On Family Or Work...'

'I Don't Want To Compromise On Family Or Work...'

Rediff.com30 May 2025

Dr Ganesh Natarajan offers practical advice on the importance of skill development.

US FDA tightens screws on sale of diet supplements

US FDA tightens screws on sale of diet supplements

Rediff.com29 Jun 2007

The US Food and Drug Administration has tightened rules for selling dietary supplements in the US market, making compliance with current good manufacturing practices mandatory for manufacturers.

Guidance, stock rally may keep HAL under pressure

Guidance, stock rally may keep HAL under pressure

Rediff.com5 Jun 2025

The performance of Hindustan Aeronautics Limited (HAL) for 2024-25 (FY25) was driven by improved margins and lower provisions. The order book as of March was of Rs 1.8 trillion, with inflows of Rs 1 trillion during FY25.

Top 10 Courses For Commerce Students After Class 12

Top 10 Courses For Commerce Students After Class 12

Rediff.com2 Jun 2025

In today's dynamic economic landscape, commerce and management education is crucial for a global career, says Nayagam PP.

Small drug makers face closure

Small drug makers face closure

Rediff.com29 Dec 2003

FULL TEXT: President's address to the nation on I-Day eve

FULL TEXT: President's address to the nation on I-Day eve

Rediff.com15 Aug 2025

President Droupadi Murmu's address to the nation on the eve of the 79th Independence Day.

50 million doses of Covaxin set to expire in 2023

50 million doses of Covaxin set to expire in 2023

Rediff.com6 Nov 2022

Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.

'This Year, We Will Commence Full Refit Of B787s'

'This Year, We Will Commence Full Refit Of B787s'

Rediff.com16 Jun 2025

'That refresh programme -- because they are big aircraft and we cannot ground them all at the same time -- will last well into 2027.'

Dr Reddy's sued in US court by S Korean pharma co

Dr Reddy's sued in US court by S Korean pharma co

Rediff.com27 Jan 2017

Suit alleges fraud by hiding significant deficiencies in CGMP regulations enforced by US health regulator.

There will be some pain: Trump's message to Americans

There will be some pain: Trump's message to Americans

Rediff.com3 Feb 2025

United States President Donald Trump on Sunday criticised the trade deficits that the US has with Canada, Mexico, China, and argued that America should no longer 'subsidise' other countries, and urged businesses to manufacture domestically to avoid tariffs.

Trump's Tariff Tsunami: Will India Sink or Reform?

Trump's Tariff Tsunami: Will India Sink or Reform?

Rediff.com21 Apr 2025

The Trump trade shock is a chance to push long-overdue reforms, rather than tinker with tariffs to appease the US, suggests M Govinda Rao.

UK warning to affect herbal exports

UK warning to affect herbal exports

Rediff.com24 Aug 2005

The warnings issued by Britain and Canada against the use of some Indian herbal medicines on the ground that they contain dangerous levels of heavy metals, may affect the export of medicinal plants in the global market.

Budget 2025: More Jobs Via Thriving Farms and MSME Growth

Budget 2025: More Jobs Via Thriving Farms and MSME Growth

Rediff.com4 Feb 2025

The most striking features of this Budget was its focus on simplification and improving the ease of doing business in India, asserts Kaku Nakhate.

Why So Much Hatred For English?

Why So Much Hatred For English?

Rediff.com21 Jul 2025

There is no guarantee that if we speak in only Indian languages, all our faults will be washed away and India will shine. Why then do they bully and belittle the English-speaking? asks Shyam G Menon.

Which is the new battleground in tax disputes?

Which is the new battleground in tax disputes?

Rediff.com25 Jun 2025

In October 2024, Jindal Stainless challenged a Goods and Services Tax (GST) notice in the Delhi high court. It was about corporate guarantees issued to related parties by its former group company, Jindal Stainless (Hisar), before their merger in March 2023.

USFDA issues warning against Cadila Pharmaceuticals

USFDA issues warning against Cadila Pharmaceuticals

Rediff.com12 Nov 2014

The FDA issued the letter on October 15, and has given the company 15 days to respond.